Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sante Beauteye is a premium over-the-counter (OTC) ophthalmic solution developed and manufactured by Santen Pharmaceutical Co., Ltd. Classified as a Class 2 OTC medicine in Japan, it is formulated to address eye fatigue, redness, and irritation caused by modern environmental stressors such as digital screen use and UV exposure. The product contains a combination of five active ingredients: taurine to enhance ocular metabolism, chondroitin sulfate sodium to protect and moisturize the cornea, vitamin B12 (cyanocobalamin) to relieve ciliary muscle strain, tetrahydrozoline hydrochloride to reduce conjunctival congestion through vasoconstriction, and chlorpheniramine maleate to alleviate itching and inflammation. It is widely recognized for its distinctive red color and elegant packaging designed to resemble a perfume bottle.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sante Beauteye.